Whalen Wealth Management Inc. Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Whalen Wealth Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 26,292 shares of the company's stock, valued at approximately $404,000.

Other large investors also recently bought and sold shares of the company. Oarsman Capital Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $44,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $54,000. IFP Advisors Inc increased its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its position in Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after acquiring an additional 949 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president now directly owns 9,989 shares in the company, valued at $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.55% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $21.00 to $23.00 in a research note on Monday, May 12th. The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Truist Financial began coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $24.44.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $16.97 on Monday. The firm's fifty day moving average is $16.39 and its two-hundred day moving average is $17.41. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a market cap of $19.46 billion, a P/E ratio of -14.75, a P/E/G ratio of 0.87 and a beta of 0.60. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.48 earnings per share. As a group, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.